Edwards Lifesciences Corporation

Revenue is per-procedure rather than contractual; aortic stenosis is progressive and non-discretionary, and Edwards has grown net sales every year from FY2021 through FY2025 including through the COVID recovery. No backlog or contractual forward visibility exists, as hospital procurement is made procedure-by-procedure.

TAVR (SAPIEN platform) represented 74% of FY2025 net sales; Surgical Heart Valves contributed 17% and TMTT 9%. Both TAVR and Surgical Heart Valves address the same clinical condition (predominantly aortic stenosis), limiting the true diversification benefit of the second segment.

The United States represented 58% of FY2025 net sales, with Europe at approximately 25%, Japan at approximately 6%, and the remainder distributed across approximately 100 countries. Single-market concentration above half of revenue means CMS reimbursement and U.S. hospital capacity decisions carry disproportionate weight.

Gross margins have held above 75% across FY2021-FY2025, reflecting the high-value-device economics of transcatheter valve systems; operating leverage is meaningful as TMTT scales toward its $2B annual target by 2030. R&D reinvestment of approximately 18% of revenues limits near-term margin expansion but supports the next-generation product pipeline.

TAVR and TMTT procedures address life-threatening or severely symptomatic structural heart disease, creating medically non-discretionary demand and durable hospital repeat-purchase patterns. Revenue is transactional per implant rather than contractual or subscription, but clinical necessity supports volume stability.